What Clinicians Want to Know: Addressing Community Oncologists’ Questions About the Roles of CAR T-Cell Therapy and Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma

A CME Symposium Held Adjunct with the 2026 ASCO® Annual Meeting

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois
Phone: (312) 922-4400

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

Meeting Room
Continental Room C (Lobby Level)

No registration fee is charged for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.

Faculty

Joshua Brody

Faculty

Joshua Brody

MD

The Tisch Cancer Institute at Mount Sinai, New York, New York

Director, Lymphoma Immunotherapy Program

Icahn School of Medicine at Mount Sinai, New York, New York

Faculty Member, Icahn Genomics Institute

Manali Kamdar

Faculty

Manali Kamdar

MD, MBBS

University of Colorado Cancer Center Aurora, Colorado

Associate Professor Clinical Director of Lymphoma Services Morton and Sandra Saffer Endowed Chair in Hematology Research Division of Hematology, Hematologic Malignancies

Tycel Phillips

Faculty

Tycel Phillips

MD

City of Hope Comprehensive Cancer Center, Duarte, California

Associate Professor, Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation

Jason Westin

Faculty

Jason Westin

MD, MS

The University of Texas MD Anderson Cancer Center Houston, Texas

Director, Lymphoma Clinical Research Section Chief, Aggressive Lymphoma Professor, Department of Lymphoma and Myeloma

Jeremy S Abramson

Moderator

Jeremy S Abramson

MD, MMSc

Massachusetts General Hospital, Boston, Massachusetts

Director, Center for Lymphoma

Harvard Medical School, Boston, Massachusetts

Professor of Medicine

Additional faculty to be announced.

This activity is supported by educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group, and Genmab US Inc.

Not an official event of the 2026 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL)

  • Factors such as patient age, performance status, comorbidities or prior therapies influencing eligibility for CAR T-cell therapy
  • Long-term efficacy and safety data with axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tis-cel) and lisocabtagene maraleucel (liso-cel) for multiregimen-relapsed DLBCL
  • Major findings from Phase III studies with CAR T-cell therapy as second-line treatment for DLBCL
  • FDA approvals of axi-cel and liso-cel as second-line therapy, and appropriate identification of candidates for this strategy
  • Rationale for, preliminary results with and ongoing assessment of CAR T-cell therapy in the up-front setting for high-risk disease
  • Early results with and ongoing investigation of other CAR T-cell platforms for DLBCL (eg, rapcabtagene autoleucel)

MODULE 2: Bispecific Antibody Therapy for DLBCL

  • Pharmacologic similarities and differences among the various approved and investigational CD20 x CD3 bispecific antibodies for non-Hodgkin lymphoma (NHL)
  • Key efficacy and safety outcomes from pivotal studies of glofitamab and epcoritamab monotherapy for relapsed/refractory (R/R) DLBCL
  • FDA approvals of glofitamab and epcoritamab; evidence-based sequencing of and selection between these agents for R/R DLBCL
  • Published data with and potential role of odronextamab monotherapy for R/R DLBCL
  • Available Phase III findings with bispecific antibodies in combination with other anticancer therapies and in earlier settings for DLBCL, including those from STARGLO, SUNMO and Part 1 of the OLYMPIA-3 study
  • Early data with and ongoing assessment of other bispecific antibody-containing combination strategies for DLBCL

MODULE 3: CAR T-Cell Therapy for Other Lymphoma Subtypes

  • Extended follow-up with axi-cel, tis-cel and liso-cel for multiregimen-relapsed follicular lymphoma (FL); appropriate selection of candidates with FL for CAR T-cell therapy
  • Outcomes from the high-risk second-line subgroup of the Phase II TRANSCEND FL study of liso-cel for R/R FL; implications, if any, for therapeutic sequencing
  • Ongoing and planned trials (eg, ZUMA-22, LEDA, TRANSFORM FL) of CAR T-cell therapy for R/R FL
  • Key clinical research findings with brexucabtagene autoleucel and liso-cel for R/R mantle cell lymphoma (MCL)
  • Optimal integration of CAR T-cell therapy into current MCL treatment algorithms
  • Published results with liso-cel for R/R marginal zone lymphoma (MZL); FDA priority review status and potential clinical role

MODULE 4: Bispecific Antibody Therapy for FL and Other Lymphoma Subtypes

  • Available data establishing the efficacy and safety of mosunetuzumab and epcoritamab monotherapy for R/R FL
  • FDA approval of mosunetuzumab and epcoritamab monotherapy for FL after 2 or more lines of systemic therapy; optimal incorporation opposite other available treatment options
  • Published data with odronextamab monotherapy for R/R FL from the ELM-1 and ELM-2 trials
  • Ongoing FDA review of odronextamab monotherapy for R/R FL; potential clinical role
  • Emerging outcomes from the Phase III EPCORE FL-1 study supporting the recent FDA approval of epcoritamab in combination with lenalidomide and rituximab for R/R FL; selection of patients appropriate for this approach
  • Available research findings with other bispecific antibody-based combination regimens for FL, including in the first-line setting
  • Available data with, ongoing investigation of and potential clinical role of bispecific antibodies for other NHL subtypes (eg, MCL, MZL)

MODULE 5: Tolerability Considerations with CAR T-Cell Therapy and Bispecific Antibodies

  • Comparative frequency and severity of cytokine release syndrome (CRS) and neurotoxicity/immune effector cell-associated neurotoxicity syndrome (ICANS) with available anti-CD19 CAR T-cell constructs for various NHL subtypes
  • Guideline-endorsed approaches for the mitigation, monitoring and management of CRS and neurotoxicity/ICANS; role of corticosteroids, tocilizumab and other supportive care interventions
  • Rationale for and potential implications of the recent elimination of the Risk Evaluation and Mitigation Strategy for patients receiving CAR T-cell therapy
  • Long-term tolerability and toxicity considerations (eg, delayed neurotoxicity, cytopenias, hypogammaglobulinemia, infection, secondary malignancy) with CAR T-cell therapy
  • Incidence, severity and time course of CRS and neurotoxicity/ICANS with bispecific antibody therapy for NHL
  • Other tolerability concerns with bispecific antibodies for NHL; recommended mitigation and management protocols

Target Audience
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphoma.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Develop an understanding of the biological rationale for the development of CD19-directed chimeric antigen receptor (CAR) T-cell therapy as a targeted strategy to eliminate cancer cells in patients with various forms of non-Hodgkin lymphoma (NHL).
  • Appraise the scientific justification for the evaluation of CD20 x CD3 bispecific antibodies for patients with various forms of NHL, and assess the similarities and differences among currently available agents in this class.
  • Evaluate the available clinical research database with CD19-directed CAR T-cell therapy and CD20 x CD3 bispecific antibodies in the management of relapsed/refractory diffuse large B-cell lymphoma, and optimally incorporate these approaches into current treatment algorithms.
  • Assess available research findings with CD19-directed CAR T-cell therapy and CD20 x CD3 bispecific antibodies for other B-cell lymphomas, including follicular lymphoma and mantle cell lymphoma, and identify patients for whom these novel approaches should be considered or recommended.
  • Recognize adverse events associated with available and investigational CAR T-cell therapies and bispecific antibodies, and implement strategies to educate patients and manage complications.
  • Recall ongoing research attempting to further define the optimal role of CAR T-cell therapy and bispecific antibody-based strategies for NHL, and counsel patients about potential clinical trial participation.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY — Dr Brody has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Kamdar — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group; Data and Safety Monitoring Boards/Committees: Bristol Myers Squibb, Celgene Corporation, Genentech, a member of the Roche Group. Dr Westin — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, Faeth Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, GSK, Immunocore, ImmunoGen Inc, Incyte Corporation, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mereo BioPharma, NGM Biopharmaceuticals, Nuvectis Pharma Inc, Ottimo Pharma, Pfizer Inc, pharmaand GmbH, PMV Pharma, Seagen Inc, Verastem Inc, Zentalis Pharmaceuticals, ZielBio; Contracted Research: AstraZeneca Pharmaceuticals LP, Avenge Bio, Bayer HealthCare Pharmaceuticals, Bio-Path Holdings Inc, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Genmab US Inc, GSK, Jazz Pharmaceuticals Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mereo BioPharma, Novartis, Nuvectis Pharma Inc, Pfizer Inc, pharmaand GmbH, Verastem Inc, Zentalis Pharmaceuticals. Additional faculty to be announced.

MODERATOR
Dr Abramson — Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Celgene Corporation, Foresight Diagnostics, Genentech, a member of the Roche Group, Gilead Sciences Inc, Interius BioTherapeutics, Miltenyi Biotec, Novartis, Roche Laboratories Inc, Seagen Inc; Contracted Research: Bristol Myers Squibb, Celgene Corporation, Cellectis, Genentech, a member of the Roche Group, Merck, Mustang Bio, Regeneron Pharmaceuticals Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group, and Genmab US Inc.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room C (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

You have successfully registered

See you on Sunday, May 31

Format:

Chicago, IL
Date & Time:

Sunday, May 31 7:00 PM — 9:00 PM CT

Understanding the Role and Reality of CAR (Chimeric Antigen Receptor) T-Cell Therapy for Non-Hodgkin Lymphoma (Patients)

To play this presentation please log in.

Don't have an account?

Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

Faculty

Jeremy S Abramson

Jeremy S Abramson

MD, MMSc

Massachusetts General Hospital, Boston, Massachusetts

Director, Center for Lymphoma

Harvard Medical School, Boston, Massachusetts

Professor of Medicine

Manali Kamdar

Manali Kamdar

MD, MBBS

University of Colorado Cancer Center, Aurora, Colorado

Associate Professor, Clinical Director of Lymphoma Services, Morton and Sandra Saffer Endowed Chair in Hematology Research, Division of Hematology, Hematologic Malignancies

TARGET AUDIENCE
This special webinar is designed to educate patients about CAR T-cell therapy for non-Hodgkin lymphoma. Participants will learn about what is important in a diagnosis, what treatment options are available and what side effects may be encountered.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS ACTIVITY
Video Program: This activity consists of a video component. The participant may review the faculty information and watch the video located at ResearchToPractice.com/PatientProject2025/CARTPatients/Video.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Jeremy S Abramson, MD, MMSc
Director, Center for Lymphoma
Massachusetts General Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Celgene Corporation, Foresight Diagnostics, Genentech, a member of the Roche Group, Gilead Sciences Inc, Interius BioTherapeutics, Miltenyi Biotec, Novartis, Roche Laboratories Inc, Seagen Inc; Contracted Research: Bristol Myers Squibb, Celgene Corporation, Cellectis, Genentech, a member of the Roche Group, Merck, Mustang Bio, Regeneron Pharmaceuticals Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc.

Manali Kamdar, MD, MBBS
Associate Professor
Clinical Director of Lymphoma Services
Morton and Sandra Saffer Endowed Chair in Hematology Research
Division of Hematology, Hematologic Malignancies
University of Colorado Cancer Center
Aurora, Colorado

Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Celgene Corporation, Genentech, a member of the Roche Group; Contracted Research: Novartis; Data and Safety Monitoring Boards/Committees: Celgene Corporation, Genentech, a member of the Roche Group.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from Bristol Myers Squibb and Novartis.

Release date: November 2025
Expiration date: November 2026

Understanding the Current Paradigm and New Approaches in the Care of Patients with Non-Hodgkin Lymphoma

Accreditation types: 1.75 NCPD

To play this presentation please log in.

Don't have an account?

Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

Faculty

Christopher Flowers

Faculty

Christopher Flowers

MD, MS

The University of Texas MD Anderson Cancer Center, Houston, Texas

Division Head, Division of Cancer Medicine, Chair, Professor, Department of Lymphoma/Myeloma, John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine

Manali Kamdar

Faculty

Manali Kamdar

MD, MBBS

University of Colorado Cancer Center, Aurora, Colorado

Associate Professor, Clinical Director of Lymphoma Services, Morton and Sandra Saffer Endowed Chair in Hematology Research, Division of Hematology, Hematologic Malignancies

Robin Klebig

Faculty

Robin Klebig

MSN, APRN, CNP, AOCNP

Mayo Clinic, Rochester, Minnesota

Hematology Outpatient APP Supervisor, Assistant Professor of Medicine, Nurse Practitioner, Lymphoma Group, Division of Hematology

Caitlin Murphy

Faculty

Caitlin Murphy

DNP, FNP-BC, AOCNP

Dana-Farber Cancer Institute, Boston, Massachusetts

Clinical Nurse Practitioner, Director of Advanced Practice Nursing

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of non-Hodgkin lymphoma.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with non-Hodgkin lymphoma.

LEARNING OBJECTIVES

  • Identify patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) for whom CD79b-targeted therapy as a component of first-line treatment would be appropriate.
  • Understand published clinical research findings with CD19-targeted monoclonal antibodies in combination with immunomodulatory agents in treatment for DLBCL and follicular lymphoma (FL), and employ this information in patient education discussions.
  • Appraise the biological rationale for, available research findings with and current clinical role of CD19-targeted antibody-drug conjugates in therapy for patients with relapsed/refractory (R/R) DLBCL.
  • Evaluate published clinical research findings establishing the efficacy and safety of Bruton tyrosine kinase (BTK) inhibitors as a component of first-line therapy for mantle cell lymphoma (MCL), and assess the current and potential role of various BTK inhibitor-based strategies in the care of patients newly diagnosed with the disease.
  • Appreciate the biological rationale for, available data with and current clinical role of BTK inhibitors in treatment for patients with R/R MCL, and discern how these agents can be appropriately and safely integrated into routine practice.
  • Review published clinical research findings establishing the efficacy and safety of combined BTK inhibitor/anti-CD20 antibody therapy for R/R FL, and identify patients for whom treatment with available combinations would be appropriate.
  • Recognize the spectrum, frequency and severity of adverse events associated with various therapies commonly employed in the care of patients with NHL, and consider recommended approaches to prevent, ameliorate and manage resultant side effects.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
Video Program: This educational activity for 1.75 contact hours is provided by RTP during the period of May 2025 to May 2026.

This activity is awarded 1.75 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2025/NHL/ILNA.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

FOR SUCCESSFUL COMPLETION
Video Program: This NCPD activity consists of a video component. To receive credit, the participant should review the NCPD information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ONS2025/NHL/Video/NCPD.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Christopher Flowers, MD, MS
Division Head, Division of Cancer Medicine
Chair, Professor, Department of Lymphoma/Myeloma
John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Celgene Corporation, Denovo Biopharma, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Karyopharm Therapeutics; Contracted Research: 4D Pharma PLC, AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Alaunos Therapeutics, Allogene Therapeutics, Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Cellectis, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Iovance Biotherapeutics, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Nektar Therapeutics, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Xencor; Nonrelevant Financial Relationships: Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas (CPRIT Scholar in Cancer Research), Eastern Cooperative Oncology Group, Foresight Diagnostics, National Cancer Institute, N-Power Medicine Inc, V Foundation.

Manali Kamdar, MD, MBBS
Associate Professor
Clinical Director of Lymphoma Services
Morton and Sandra Saffer Endowed Chair in Hematology Research
Division of Hematology, Hematologic Malignancies
University of Colorado Cancer Center
Aurora, Colorado

Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group; Contracted Research: Novartis; Data and Safety Monitoring Board/Committees: Celgene Corporation, Genentech, a member of the Roche Group.

Robin Klebig, MSN, APRN, CNP, AOCNP
Hematology Outpatient APP Supervisor
Assistant Professor of Medicine
Nurse Practitioner, Lymphoma Group
Division of Hematology
Mayo Clinic
Rochester, Minnesota

No relevant financial relationships to disclose.

Caitlin Murphy, DNP, FNP-BC, AOCNP
Clinical Nurse Practitioner
Director of Advanced Practice Nursing
Dana-Farber Cancer Institute
Boston, Massachusetts

Advisory Committees: Genmab US Inc, Seagen Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop NCPD activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from ADC Therapeutics and AstraZeneca Pharmaceuticals LP.

Release date: May 2025
Expiration date: May 2026

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Dr Kamdar

Module 1: Current and Future Use of Bruton Tyrosine Kinase Inhibitors for Mantle Cell Lymphoma

Dreyling M et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): A three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet 2024;403(10441):2293-306. Abstract

Dreyling M et al. Role of autologous stem cell transplantation in the context of ibrutinib-containing first-line treatment in younger patients with mantle cell lymphoma: Results from the randomized Triangle trial by the European MCL Network. ASH 2024;Abstract 240.

Jain P et al. Acalabrutinib with rituximab is highly effective first line treatment for older patients with mantle cell lymphoma. ASH 2024;Abstract 3038.

Kumar A et al. A multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-naïve, TP53-mutant mantle cell lymphoma. ASH 2023;Abstract 738.

Wang M et al. Acalabrutinib plus bendamustine and rituximab in untreated mantle cell lymphoma: Results from the phase 3, double-blind, placebo-controlled ECHO trial. EHA 2024;Abstract LBA3439.

Wang M et al. Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis. Blood Adv 2024;8(17):4539-48. Abstract

Wang M et al. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): A single-arm, phase 2 trial. Lancet Oncol 2022;23(3):406-15. Abstract

 

Module 3: Role of Loncastuximab Tesirine for Patients with Relapsed/Refractory (R/R) DLBCL

Caimi PF et al. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: Long-term efficacy and safety from the phase II LOTIS-2 study. Haematologica 2024;109(4):1184-93. Abstract

Epperla N et al. Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma. Blood Cancer J 2024;14(1):210. Abstract

Hamadani M et al. Real‐world treatment of large B‐cell lymphoma with chimeric antigen receptor T‐cell therapy after loncastuximab tesirine. EJHaem 2024;5(5):1110–3. Abstract

 

Dr Flowers

Module 2: First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) 

Palmer AC et al. Cell-of-origin subtypes and therapeutic benefit from polatuzumab vedotin. N Engl J Med 2023;389(8):764-6. Abstract

Peyrade F et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: A multicentre, single-arm, phase 2 trial. Lancet Oncol 2011;12(5):460-8. Abstract

Salles G et al. Five-year analysis of the POLARIX study: Prolonged follow-up confirms positive impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes. ASH 2024;Abstract 469.

Sehn LH et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38(2):155-65. Abstract

Teras LR et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 2016;66(6):443-59. Abstract

Tilly H et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2022;386(4):351-63. Abstract

 

Module 4: Role of Tafasitamab for Patients with R/R DLBCL and Follicular Lymphoma

Caimi PF et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2021;22(6):790-800. Abstract

Duell J et al. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: Final 5-year efficacy and safety findings in the phase II L-MIND study. Haematologica 2024;109(2):553-66. Abstract

Duell J et al. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica 2021;106(9):2417-26. Abstract

Kalakonda N et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): A single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 2020;7(7):e511-22. Abstract

Salles G et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): A multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 2020;21(7):978-88. Abstract

Sehn LH et al. Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Results from a phase 3 study (inMIND). ASH 2024;Abstract LBA-1.

Sehn LH et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: Survival update and new extension cohort data. Blood Adv 2022;6(2):533-43. Abstract

Vercellino L et al. Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv 2020;4(22):5607-15. Abstract

  • for-nurses

Optimizing the Current and Future Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

To play this presentation please log in.

Don't have an account?

Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

Faculty

Martin Hutchings

Martin Hutchings

MD, PhD

University of Copenhagen, Copenhagen, Denmark

Senior Consultant, Department of Haematology and Phase 1 Unit, Rigshospitalet, Copenhagen University Hospital, Professor of Clinical Lymphoma Research, Department of Clinical Medicine

Manali Kamdar

Manali Kamdar

MD, MBBS

University of Colorado Cancer Center, Aurora, Colorado

Associate Professor, Clinical Director of Lymphoma Services, Morton and Sandra Saffer Endowed Chair in Hematology Research, Division of Hematology, Hematologic Malignancies

Matthew Lunning

Matthew Lunning

DO

University of Nebraska Medical Center, Omaha, Nebraska

Professor, Medical Director, Gene and Cellular Therapy, Assistant Vice Chancellor for Clinical Research, Fred and Pamela Buffett Cancer Center

Gilles Salles

Gilles Salles

MD, PhD

Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York

Service Chief, Lymphoma Service, Steven Greenberg Chair

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of diffuse large B-cell lymphoma.

LEARNING OBJECTIVES

  • Apply available clinical research findings in the formation of evidence-based therapeutic approaches for patients with relapsed/refractory (R/R) DLBCL both fit and unfit for intensive therapy.
  • Evaluate the mechanisms of action of and available clinical trial findings with various CD19-directed therapies approved for R/R DLBCL, and assess the spectrum and frequency of associated toxicities.
  • Appraise the biological rationale for, recently presented research findings with and the potential clinical role of CD30-targeted antibody-drug conjugate-based therapy for R/R DLBCL.
  • Consider published research data with and the current clinical role of CD20 x CD3 bispecific antibodies for R/R DLBCL.
  • Identify patients with R/R DLBCL for whom treatment with chimeric antigen receptor T-cell therapy would be appropriate.
  • Counsel appropriate patients regarding the potential benefits of participation in ongoing clinical studies evaluating novel agents and strategies for R/R DLBCL.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Interview: Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and a short post-test, enables the participant to earn up to 2.75 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/DLBCLThinkTank2024/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Martin Hutchings, MD, PhD
Senior Consultant
Department of Haematology and Phase 1 Unit
Rigshospitalet, Copenhagen University Hospital
Professor of Clinical Lymphoma Research
Department of Clinical Medicine, University of Copenhagen
Copenhagen, Denmark

Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genmab US Inc, Janssen Biotech Inc, Merck, Roche Laboratories Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Celgene Corporation, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Boards/Committees: Genmab US Inc, Roche Laboratories Inc.

Manali Kamdar, MD, MBBS
Associate Professor
Clinical Director of Lymphoma Services
Morton and Sandra Saffer Endowed Chair in Hematology Research
Division of Hematology, Hematologic Malignancies
University of Colorado Cancer Center
Aurora, Colorado

Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Celgene Corporation, Genentech, a member of the Roche Group; Contracted Research: Novartis; Data and Safety Monitoring Boards/Committees: Celgene Corporation, Genentech, a member of the Roche Group.

Matthew Lunning, DO
Associate Professor of Medicine
Medical Director, Cellular Therapy
Associate Vice Chair of Research
Assistant Vice Chancellor for Clinical Research
Division of Hematology/Oncology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Consulting/Honoraria: AbbVie Inc, Acrotech Biopharma, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Caribou Biosciences Inc, Fate Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Nurix Therapeutics Inc, Pfizer Inc, Recordati, Regeneron Pharmaceuticals Inc, Seagen Inc, Veeva, Vittoria Biotherapeutics; Research Funding: AbbVie Inc,Bristol Myers Squibb, Fate Therapeutics, Kite, A Gilead Company.

Gilles Salles, MD, PhD
Service Chief, Lymphoma Service
Steven Greenberg Chair
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
New York, New York

Advisory Committees: AbbVie Inc, BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Nurix Therapeutics Inc, Pfizer Inc; Consulting Agreements: AbbVie Inc, ATB Therapeutics, BeiGene Ltd, Bristol Myers Squibb, Debiopharm, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Kite, A Gilead Company, ModeX Therapeutics, Molecular Partners, Orna Therapeutics, Treeline Biosciences; Contracted Research: AbbVie Inc, Genentech, a member of the Roche Group, Genmab US Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Nurix Therapeutics Inc.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, and Incyte Corporation.

Release date: February 2025
Expiration date: February 2026

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Dr Kamdar

Abramson JS et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: Primary analysis of the phase 3 TRANSFORM study. Blood 2023;141(14):1675-84. Abstract

Abramson JS et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study. Lancet 2020;396(10254):839-52. Abstract

Bishop MR et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med 2022;386(7):629-39. Abstract

Cordeiro A et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transplant 2020;26(1):26-33. Abstract

Crump M et al. Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study. Blood 2017;130(16):1800-8. Abstract

Gisselbrecht C et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28(27):4184-90. Abstract

Hill HA et al. Genetic mutations and features of mantle cell lymphoma: A systematic review and meta-analysis. Blood Adv 2020;4(13):2927-38. Abstract

Hines MR et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplant Cell Ther 2023;29(7):438.e1-16. Abstract

Jacobson CA. CD19 chimeric antigen receptor therapy for refractory aggressive B-cell lymphoma. J Clin Oncol 2019;37(4):328-35. Abstract

Kamdar M et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): Results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 2022;399(10343):2294-308. Abstract

Kramer AM et al. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: Continued durable remissions at 3-year follow-up. ASH 2024;Abstract 69.

Lee DW et al.ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells.Biol Blood Marrow Transplant 2019;25(4):625-38. Abstract

Locke FL et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022;386(7):640-54. Abstract

Locke FL et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial. Lancet Oncol 2019;20(1):31-42. Abstract

Morris EC et al. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 2022;22(2):85-96. Abstract

Rejeski K et al. CAR-HEMATOTOX: A model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood 2021;138(24):2499-513. Abstract

Riedell PA et al. Rapcabtagene autoleucel (YTB323) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Phase II trial clinical update. ASH 2024;Abstract 67.

Schuster SJ et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): A multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2021;22(10):1403-15. Abstract

Sehgal A et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): An open-label, phase 2 study. Lancet Oncol 2022;23(8):1066-77. Abstract

 

Prof Hutchings

Abramson J et al. Glofitamab plus gemcitabine and oxaliplatin (GLOFIT-GEMOX) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Results of a global randomized phase III trial (STARGLO). EHA 2024;Abstract LB3438.

Abramson JS et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study. Lancet 2020;396(10254):839-52. Abstract

Bannerji R et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): Results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol 2022;9(5):e327-39. Abstract

Budde LE et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: Phase I dose-escalation study. J Clin Oncol 2022;40(5):481-91. Abstract

Crochet G et al. Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma. Blood 2024;144(3):334-8. Abstract

Dickinson MJ et al. Fixed-duration glofitamab monotherapy continues to demonstrate durable responses in patients with relapsed or refractory large B-cell lymphoma: 3-year follow-up from a pivotal phase II study. ASH 2024;Abstract 865.

Dickinson MJ et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2022;387(24):2220-31. Abstract

Dickinson MJ et al. Glofitamab induces durable complete remissions and has favorable safety in patients with relapsed/refractory diffuse large B-cell lymphoma and ≥2 prior therapies: Pivotal phase II expansion results. EHA 2022;Abstract S220.

Hiemstra IH et al. Potent anti-tumor activity of DuoBody®-CD3xCD20 in preclinical models in vitro and in vivo. EHA 2019;Abstract PS1301.

Hutchings M et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An open-label, phase 1/2 study. Lancet 2021;398(10306):1157-69. Abstract

Hutchings M et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: A phase I trial. J Clin Oncol 2021;39(18):1959-70. Abstract

Lussana F et al. Immunotherapy of acute lymphoblastic leukemia and lymphoma with T cell-redirected bispecific antibodies. J Clin Oncol 2021;39(5):444-55. Abstract

Thieblemont C et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I/II trial. J Clin Oncol 2023;41(12):2238-47. Abstract

Vose JM et al. 3-year update from the Epcore NHL-1 trial: Epcoritamab leads to deep and durable responses in relapsed or refractory large B-cell lymphoma. ASH 2024;Abstract 4480.

 

Prof Salles

Caimi PF et al. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: Long-term efficacy and safety from the phase II LOTIS-2 study. Haematologica 2024;109(4):1184-93. Abstract

Caimi PF et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2021;22(6):790-800. Abstract

Cheson BD et al. Diffuse large B-cell lymphoma: New targets and novel therapies. Blood Cancer J 2021;11(4):68. Abstract

Crombie JL et al. Real-world outcomes with novel therapies in R/R DLBCL. ASCO 2023;Abstract 7552.

Duell J et al. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: Final 5-year efficacy and safety findings in the phase II L-MIND study. Haematologica 2024;109(2):553-66. Abstract

Duell J et al. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica 2021;106(9):2417-26. Abstract

Kim C et al. Real-world outcomes of polatuzumab vedotin with bendamustine and rituximab as salvage and bridge therapy to CAR T-cell treatment in relapsed/refractory diffuse large B-cell lymphoma. ASH 2024;Abstract 3107.

Paillassa J et al. Tafasitamab lenalidomide in relapsed/refractory large B-cell lymphomas: A multicentric real-world French experience study. Hematological Oncology 2023;41:591-2. Abstract

Qualls DA et al. Tafasitamab and lenalidomide in large B-cell lymphoma: Real-world outcomes in a multicenter retrospective study. Blood 2023;142(26):2327-31. Abstract

Salles G et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): A multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 2020;21(7):978-88. Abstract

Saverno K et al. Real-world effectiveness of tafasitamab (tafa) for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) in the United States. ASH 2024;Abstract 2375.

Sehn LH et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: Survival update and new extension cohort data. Blood Adv 2022;6(2):533-43. Abstract

Sehn LH et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38(2):155-65. Abstract

Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med 2021;384(9):842-58. Abstract

 

Dr Lunning

Bartlett NL et al. Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma. J Clin Oncol 2025;[Online ahead of print]. Abstract

Bartlett NL et al. Outcomes in older patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) from the ECHELON-3 study. ASH 2024;Abstract 4483.

Chavez JC et al. Efficacy and safety of golcadomide, a novel cereblon E3 ligase modulator (CELMoD) agent, combined with rituximab in a phase 1/2 open-label study of patients with relapsed/refractory non-Hodgkin lymphoma. ASH 2023;Abstract 4496.

Kim JA et al. Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study. ASCO 2024;Abstract LBA7005.

Matasar M et al. Efficacy and safety of odronextamab monotherapy in patients (pts) with diffuse large B-cell lymphoma (DLBCL) progressing after CAR T-cell therapy: Primary analysis from the ELM-1 study. ASH 2024;Abstract 866.

Michot J-M et al. Longer follow-up of golcadomide (GOLCA), a cereblon E3 ligase modulator (CELMoD™) agent ± rituximab (RTX), in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). ASH 2024;Abstract 869.